Mdd Clinical Trials
Here are the 6 most popular medical studies for mdd
Behavioural Intervention
BI 1569912 for Major Depressive Disorder
This trial is looking for adults between 18 and 65 years old who have major depressive disorder and have not responded to previous treatments. The study is testing a medicine called BI 1569912 to
Behavioral Intervention
Sham neurofeedback +1 More for Major Depressive Disorder
This trial aims to investigate the relationship between brain connectivity and repetitive negative thinking in individuals with depression. The researchers will use a technique called real-time fMRI neurofeedback to reduce the connectivity between certain brain regions
Popular filter options for mdd trials
Persistent Depressive Disorder Clinical Trials
View 72 Persistent Depressive Disorder medical studies.
Selective Serotonin Reuptake Inhibitor
Escitalopram + Brexpiprazole for Depression
This trial will test a predictive biomarker algorithm to help predict treatment outcome for patients with major depressive episodes. The algorithm uses data from previous studies on clinical features, imaging, EEG, and molecular information.
Antidepressant
Bupropion for Depression
This trial is designed to test the safety and effectiveness of a new medication by comparing it to a placebo. The trial will involve multiple centers and neither the participants nor the researchers will know who is receiving the new medication or the placebo.
Serotonin-Norepinephrine Reuptake Inhibitor
Desvenlafaxine Succinate for Menopause
The main objective of this study is to characterize a range of brain activation symptoms associated with depression and response to treatment in midlife men and women with MDD, using MRI and functional MRI. Moreover, in the female sub-group, the investigators will examine whether these brain activation symptoms are related to menopausal symptoms (i.e., hot flashes and night sweats). Also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.
Phase 3 Mdd Clinical Trials
View 99 phase 3 mdd medical studies.
Serotonin-Norepinephrine Reuptake Inhibitor
Desvenlafaxine Succinate for Menopause
The main objective of this study is to characterize a range of brain activation symptoms associated with depression and response to treatment in midlife men and women with MDD, using MRI and functional MRI. Moreover, in the female sub-group, the investigators will examine whether these brain activation symptoms are related to menopausal symptoms (i.e., hot flashes and night sweats). Also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.
Seltorexant for Depression
This trial is testing whether seltorexant can improve depressive symptoms in people with MDD who have had an inadequate response to current antidepressant therapy with an SSRI or SNRI. The trial will also assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in people with MDD.
Mdd Clinical Trials With No Placebo
View 99 mdd medical studies that do not have a placebo group.
Behavioral Intervention
Social-Cognitive Skills Training for Schizophrenia
This trial will adapt an evidence-based social cognitive skills intervention for use with Veterans in a work setting, in order to help them better understand and manage social interactions.
View More Mdd Trials
See another 69 medical studies focused on mdd.
Frequently Asked Questions
Introduction to mdd
What are the top hospitals conducting mdd research?
When it comes to advancing the treatment options for Major Depressive Disorder (MDD), several hospitals are making significant contributions through their clinical trials. In Orlando, APG Research, LLC is at the forefront with four active MDD trials and a total of five completed trials since they started their pioneering research in 2018. Similarly, Baber Research Group in Naperville has been instrumental in the field, currently conducting four ongoing MDD trials while having accomplished nine previous studies since initiating their first trial back in 2012.
Moving on to Gainesville, Sarkis Clinical Trials continues to play a crucial role with four active MDD trials and an impressive history of twenty-two completed studies since recording their first trial in 2004. Meanwhile, at the National Institutes of Health Clinical Center in Bethesda—a renowned medical institution—researchers are also dedicatedly working towards advancements in MDD treatment. They have developed four active clinical trials for this condition and have completed nine previous studies after starting their initial trial back in 2001.
Lastly, Proscience Research Group based out of Culver City may be relatively new to the scene but has wasted no time contributing to MDD research. With three ongoing clinical trials focused on this mental health disorder and already completing three others since recording their first trial just last year (2020), they are quickly establishing themselves as a prominent player within the medical community.
These hospitals' commitment to finding innovative ways to treat Major Depressive Disorder is inspiring not only for patients who suffer from this condition but also for healthcare professionals worldwide seeking effective solutions. Through these collaborative efforts between researchers and participants alike, there is hope that breakthroughs will continue to emerge leading us towards improved treatments and ultimately better outcomes for individuals grappling with MDD.
Which are the best cities for mdd clinical trials?
Miami, Florida; New york, New York; Orlando, Florida; San Diego, California; and Houston, Texas are the top cities for major depressive disorder (MDD) clinical trials. Miami leads with 26 active trials investigating treatments like Aticaprant, REL-1017, and Seltorexant. Following closely behind is New York with 18 ongoing studies focusing on similar interventions. Orlando has 16 active trials exploring options such as Seltorexant and TNX-601 ER. Meanwhile, both San Diego and Houston offer 14 active MDD trials each that include investigational drugs like Lumateperone and Esketamine. These cities serve as hubs of research to advance our understanding of MDD treatment options and potentially improve patient outcomes.
Which are the top treatments for mdd being explored in clinical trials?
Exciting developments are underway in the realm of MDD treatments, with several interventions taking center stage in clinical trials. Leading the charge is psilocybin, a substance being tested in five active trials for MDD. Since its initial listing in 2017, it has accumulated an impressive portfolio of 13 all-time trials focused on this condition. Another promising contender is aticaprant, currently involved in three ongoing trials and making waves since its introduction in 2022. Also showing potential are seltorexant and lumateperone, both engaged in three active MDD studies since their debut on the scene back in 2020. Rounding out the top treatments is left dorsolateral prefrontal cortex (L-DLPFC), which shows promise despite having only two active trials to date. As researchers continue to delve deeper into these innovative therapies, hope grows brighter for individuals battling MDD around the world.
What are the most recent clinical trials for mdd?
Exciting advancements are being made in the field of Major Depressive Disorder (MDD) research, with recent clinical trials exploring new treatment options. One such trial focuses on esketamine, a medication that has shown promise in treating MDD. Another study investigates the use of ketamine combined with perampanel as a potential therapy for individuals with MDD. Additionally, researchers are studying the effects of high CBD [25:1] and REL-1017 25 mg on patients diagnosed with MDD. Lastly, omega-3 supplementation is being explored as a possible adjunctive treatment for individuals living with this debilitating condition. These innovative trials offer hope to those affected by MDD and signify significant progress towards improving outcomes in its management.
What mdd clinical trials were recently completed?
Several notable clinical trials for major depressive disorder (MDD) have recently concluded, showcasing advancements in treatment options. In June 2022, Alto Neuroscience successfully completed a trial evaluating the ALTO-100 PO Tablet's efficacy. Furthermore, Alto Neuroscience concluded two more trials involving the ALTO-100 and ALTO-300 PO tablets in December 2021. Other noteworthy completed trials include Neurocrine Biosciences' study on NBI-1065846 in November 2021 and Cerevel Therapeutics' investigation of CVL-354 in October 2021. These recent milestones highlight ongoing efforts to address MDD through innovative therapeutic approaches, providing hope for individuals grappling with this challenging condition.